Showing 1651-1660 of 1692 results for "".
- Vazegepant Advances to Phase 3 Trials for Acute Migraine Treatmenthttps://practicalneurology.com/news/vazegepant-advances-to-phase-3-trials-for-acute-migraine-treatment/2469198/It has previously been reported that intranasal vazegepant (Biohaven Pharmaceutical, New Haven, CT) 10 mg and 20 mg achieved statistical superiority to placebo on the coprimary regulatory endpoints of pain freedom and freedom from most bothersome symptoms at 2 hours in a phase 2/3 dose-finding tr
- Alzheimer Diagnoses Increase Significantly in Adults from 2013-2017https://practicalneurology.com/news/alzheimer-diagnoses-increase-significantly-in-adults-from-2013-2017/2469175/The number of Americans diagnosed with early-onset dementia or Alzheimer disease (AD) increased by 200% from 2013 to 2017. The average age of a person living with either form of dementia is 49. The findings came from a new Blue Cross Blue Shield Association (BCBSA) report, "Early-Onset Demen
- Study Finds that Ping-Pong May Benefit People with Parkinson Diseasehttps://practicalneurology.com/news/study-finds-that-ping-pong-may-benefit-people-with-parkinson-disease/2469167/A preliminary study showed a game of ping-pong may have potential as a form of physical therapy for Parkinson’s disease (PD). Individuals with PD who participated in a ping-pong exercise program once a week for 6 months showed improvement in symptoms. In the study, parti
- Clinical Trial to Compare Stem Cell Treatment to High-Efficacy Biologics for Treatment of Relapsing Multiple Sclerosishttps://practicalneurology.com/news/clinical-trial-to-compare-stem-cell-treatment-to-high-efficacy-biologics-for-treatment-of-relapsing-multiple-sclerosis/2469126/A clinical trial will test autologous hematopoietic stem cell treatment (AHSCT) against the best available biologic therapies for severe forms of relapsing multiple sclerosis (MS). The trial will compare the safety, efficacy, and cost-effectiveness of the 2 therapeutic approaches and has begun en
- Mixed Martial Artists and Boxers Show Different Effects From Head Injurieshttps://practicalneurology.com/news/mixed-martial-artists-and-boxers-show-different-effects-from-head-injuries/2469120/A new study shows different effects in the brain for younger current fighters compared with older, retired fighters. The study is published in the December 23, 2019, online issue of Neurology, the medical journal of the American Academy of Neurology. Both the current and former fighters ha
- Perampanel Treatment for Partial-Onset and Secondary Generalized Tonic-Clonic Seizures Provides Durable Reduction in Seizure Frequency in Phase 3 and Phase 4 Trialshttps://practicalneurology.com/news/perampanel-treatment-for-partial-onset-seizures-and-generalized-tonic-clonic-seizures-provides-durable-reduction-in-seizure-frequency-in-phase-3-and-phase-4-trials/2469105/In the FREEDOM study (NCT03201900), a phase 3 open-label study, perampanel (Fycompa; Eisai, Woodcliff Lake, NJ) was used as monotherapy to treat study participants, age 12 years or more, who were newly diagnosed with partial-onset sei
- A New Tau Aggregation Inhibitor Arrives on the Scenehttps://practicalneurology.com/news/a-new-tau-aggregation-inhibitor-arrives-on-the-scene/2469076/As published today in the Journal of Alzheimer’s Disease, a new oral small molecule drug (Oligomerix, Bronx, NY) has been shown, in the htau mouse, to inhibit formation of neurotoxic tau oli
- Reldesemtiv Slowed Disease Progression in Trial Participants With Relatively Faster Progressing Amyotrophic Lateral Sclerosishttps://practicalneurology.com/news/reldesemtiv-slowed-disease-progression-in-trial-participants-with-relatively-faster-progressing-amyotrophic-lateral-sclerosis/2469041/Post hoc analysis of the phase 2 FORTITUDE-ALS trial (NCT03160898) suggests some participants with amyotrophic lateral sclerosis (ALS) treated with reldesemtiv (Cytokinetics, San Francisco, CA) had slowed disease progression.
- New Sumatriptan Intranasal Spray Launch Announcedhttps://practicalneurology.com/news/new-sumatriptan-intranasal-spray-launch-announced/2469038/An intranasal form of sumatriptan (Tosymra Nasal Spray; Upsher-Smith Laboratories, Maple Grove, MN), approved by the Food and Drug Administration (FDA) earlier this year, has been launched for acute treatment of migraine attack with or without aura in adults. This is a new strengt
- Pimavanserin Also Effective as Adjunct Treatment for Major Depressive Disorderhttps://practicalneurology.com/news/pimavanserin-also-effective-as-adjunct-treatment-for-major-depressive-disorder/2469034/Approved for treatment of psychosis in Parkinson’s disease (PD) and with positive clinical trial results for treatment of psychosis in other forms of dementia, pimavanserin (Nuplazid; Acadia, Pharmaceuticals, San Diego, CA) may also be effective as adjunctive treatment for major depressive